Four writers. One standard.
Four beats, split the way the decisions actually split: what the trials show, what it costs, what the molecule does, and whether the format you are being sold delivers anything. Each writer works under a consistent pen name — long-standing practice in science and medical journalism.
These are pen names and each profile says so in its first line. We attach no degrees, no institutional affiliations and no clinical credentials to them, because we do not have any to attach and inventing them is the oldest trick in this category. What is real is the sourcing: every figure, dose and claim traces to the trial, the label or the paper of record, checked against the database before it published. Judge the citations.
Beats are stable on purpose. The same name always covers the same ground, so if you disagree with how this site reads the evidence on injections, you know exactly whose reasoning to argue with.
Miriam Hollis
Evidence & trialsWhat the NAD⁺ trials actually measured, and what they did not.
View profile →Desmond Okafor
Cost & accessWhat NAD⁺ therapy costs per milligram, and what the headline price hides.
View profile →Camille Duarte
Biochemistry & mechanismThe salvage pathway, the precursors, and where mechanism outruns evidence.
View profile →Arjun Mehta
Formats & deliveryInjection, IV, intranasal, transdermal, oral — and what reaches the bloodstream.
View profile →How we research and where we draw the line is set out in our methodology and editorial policy.